From our survey

Clinic visits versus at-home ketamine, side by side

Ask people how they would want this treatment delivered and they do not split evenly. In our survey, 44 percent wanted a clinic and 22 percent wanted it at home over telehealth; another 23 percent preferred to start at a clinic and finish at home, and 11 percent had no preference.

Those figures come from a poll we commissioned and paid for, covering 443 adults in ten Midwest states, and they come from the panel's completed validation. What follows weighs the three routes people named: what each asks of you in time and travel, how coverage tends to behave, and how many respondents leaned toward it.

One boundary first, or no comparison is honest. Spravato, an esketamine nasal spray, carries approval for treatment-resistant depression, and each dose happens in a certified setting with a clinician monitoring you afterward. Ketamine a remote prescriber sends you to use at home is a different category with different oversight. These are not tiers of one service, so keep them separate as you read.

Route one: the in-person clinic

You travel to a certified site, take the dose there, and stay while staff watch you. This is where the approved option lives, and the only place it lives. Brain Recovery Centers describes its in-clinic Spravato process if you want to see this route up close.

• Time: a real appointment block, most of it monitoring rather than the dose itself, repeated on a schedule the clinician sets.
• Travel: every session, both directions, and assume you are not driving yourself home.
• Supervision: continuous and in the room, from someone trained who can respond immediately.
• Coverage: this route has a billing pathway, usually with prior authorization, records of earlier treatments that failed, and some waiting.
• Support in our survey: the largest group, 44 percent.

You trade hours and miles for oversight and a plausible claim.

Route two: at-home telehealth

You meet a prescriber by video and, if prescribed, take the medication at home. This is not a remote version of the approved treatment; it is a separate market with less supervision and far less consistency between providers.

• Time: short appointments, no waiting room, which is the whole appeal.
• Travel: none, which matters if you are rural, without a car, working two shifts, or caring for someone who cannot be left alone.
• Supervision: whatever that provider builds in, and it varies enormously. Ask exactly who is reachable, when, and how quickly.
• Coverage: usually a visible cash price, and usually not something your plan pays.
• Support in our survey: 22 percent.

It mirrors route one: you gain access and give up the room, the monitoring, and usually the coverage. Whether that trade is safe for you is a clinician's question, answered from your health history.

Route three: start in a clinic, then move home

Another 23 percent chose a sequence rather than a place: begin where supervision is dense, then step down as things settle.

• Time: front-loaded; the early weeks look like route one, and later phases depend on your response.
• Travel: heaviest at the start, by design.
• Supervision: full at first, then whatever a clinician judges right, which may simply be more in-person care.
• Coverage: follows whichever treatment you are on at each stage, so it can change midstream.
• Support in our survey: 23 percent, a point above pure at-home care.

Be careful here. This is the route people find most reasonable and the hardest to promise. No provider can commit to a step-down to home care in advance, because that call belongs to a clinician watching your response. A site that promises the sequence up front is selling something it does not control.

What the money actually decides

We gave respondents a blunt tradeoff: your plan pays and you clear more hurdles, or you pay and begin sooner. Half, 51 percent, took the slower covered path; 23 percent would fund it themselves; the remaining 26 percent could not say.

Half this market will sit through prior authorization to keep a claim alive, which points hard at route one, because the covered pathway and the supervised setting are the same pathway. The delivery answer and the coverage answer lining up is no coincidence.

The payer mix underneath matters too. With more than one source allowed, commercial insurance led at 39 percent, Medicaid was close behind at 37, and Medicare followed at 23; 9 percent had no coverage and 5 percent named TRICARE. Do not assume a cash-pay audience.

Approval pulls the same way. FDA approval settled the matter outright for 19 percent and weighed heavily for another 40 percent. For that 59 percent, the distinction at the top of this page is the whole decision, not a technicality.

How to decide

• Name the treatment first. Ask any provider whether it offers FDA-approved esketamine or another form of ketamine, and get it in writing before you get a price.
• Check the gate you care about. If your plan must pay, the supervised route is where a claim can exist, so ask about prior authorization before scheduling.
• Price the friction honestly: the drive, the hours in the chair, the ride home, the missed work.
• Price the alternative honestly too. A cash price you can afford once is not one you can afford for a full course.
• Ask who is responsible for you after the dose, by name and phone number.
• Take all of it to a clinician who knows your history; suitability is a medical judgment no page can make for you.

What this comparison cannot tell you

These are stated preferences from a general-population panel, not choices by people already in treatment, and not evidence that any route helps anyone. Which payer group preferred which route is outside what this comparison reports, and we will not guess at it. The panel has signed off on all of these percentages.

One more thing outranks everything above. If your thoughts have turned toward ending your life, please get a person on the line today. A trained Lifeline counselor will answer 988, by call or text, at any hour, including right now, and you do not need the right words to use it.

Methodology

The publisher requested this research and paid its full cost. Survey 395586438 was administered through the Pollfish consumer panel, and field closed June 23, 2026. The 443 people who completed it were all 18 to 64 and lived across ten Midwest states. Multi-select items count each answer a respondent chose, pushing those totals above 100. Everything here is final, after the panel's validation.